Скачать или смотреть P2Y12 Inhibitors vs Clopidogrel in Acute MI With Cardiac Arrest or Cardiogenic Shock

Dr. Saraschandra Vallabhajosyula, an Interventional and Critical Care Cardiologist at Wake Forest University, in Winston-Salem, NC, shares results of his study appearing in the June 2022 issue of Mayo Clinic Proceedings, where he evaluated the outcomes, safety and efficacy of dual antiplatelet therapy with newer P2Y12 inhibitors compared to clopidogrel in acute myocardial infarction complicated by cardiac arrest or cardiogenic shock, He found that newer P2Y12 inhibitors were associated with lower rates of early and one-year mortality in patients experiencing acute myocardial infarction with cardiac arrest or cardiogenic shock and receiving dual antiplatelet therapy, when compared to clopidogrel. Data on major bleeding and stent thrombosis were inconclusive. Available at: https://mayocl.in/37KTOby